跳至主要内容
临床试验/NCT06660108
NCT06660108
招募中
不适用

BASES MOLECULAIRES DU DEVELOPPEMENT DU LANGAGE ORAL ET DES TROUBLES SPECIFIQUES ASSOCIES

Institut National de la Santé Et de la Recherche Médicale, France6 个研究点 分布在 1 个国家目标入组 50 人2025年3月25日

概览

阶段
不适用
干预措施
blood draw
疾病 / 适应症
Developmental Language Disorder
发起方
Institut National de la Santé Et de la Recherche Médicale, France
入组人数
50
试验地点
6
主要终点
Identification of CNV or SNV involved in neurodevelopmental disorders
状态
招募中
最后更新
12天前

概览

简要总结

Developmental Language Disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability. The prevalence of DLD is ~7%-8% or 2% if severe forms are considered.

However, the clinical heterogeneity of language disorders, the presence of co-morbidities and the inconsistent terminology used for many years have hindered research and clinical practice. Distinguishing sub-groups of children with language problems is crucial when tackling the underlying genetic causes of this disease. Recently, several studies using high-throughput sequencing have better define the genetic basis of CAS but such studies focusing on DLD are limited. The investigation of more homogeneous cohorts of individuals that clearly distinguish DLD cases, from ID and not including children with CAS should improve our understanding of the genetic basis of this disorder.

In this study, we aim to built and investigate a well-characterized cohort of DLD patients using pangenomic approaches to better define the molecular basis of this disorder. All individuals will be analyzed using chromosomal microarray analysis and whole genome sequencing. Multiple observations and preliminary results suggest strong links with the genetic basis of other neurodevelopmental disorders.

The goal is to identify CNV or SNV as causative allele or risk factor and already known to be involved in other neurodevelopmental disorders as well as potential new variants.

注册库
clinicaltrials.gov
开始日期
2025年3月25日
结束日期
2028年3月25日
最后更新
12天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
责任方
Sponsor

入排标准

入选标准

  • Inclusion Criteria:
  • Eligible families included at least one child over five years old with a formal diagnosis of severe and isolated DLD according to Phase 2 CATALISE criteria . Patients have undergone age-appropriate speech, language and reading evaluations by a speech-language physician and cognitive evaluations by a neuropsychologist, as well as evaluation by a pediatric neurologist to identify co-occurring developmental disorders (ADHD, ASD…) and a medical geneticist for known genetic disorders and genetic testing recommendations. All children included received appropriate speech therapy for at least one year, with a progress report indicating the persistence of language difficulties.

排除标准

  • Cognitive impairment with non-verbal intellectual quotient (IQ) below 2 SD assessed with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), or the Wechsler Intelligence Scale for Children (WISC-IV or V) according to the age-appropriateness, ASD, moderate to severe hearing loss, orofacial structural abnormalities, known neurological or genetic disorders at the initial assessment. None of the patients met the diagnostic criteria for CAS according to the ASHA (American Speech-Language-Hearing Association,
  • Childhood apraxia of speech www.asha.org/policy).

研究组 & 干预措施

DLD patient and relative

干预措施: blood draw

结局指标

主要结局

Identification of CNV or SNV involved in neurodevelopmental disorders

时间窗: 2 years

研究点 (6)

Loading locations...

相似试验